The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Open accessAbstract
// Asma Beldi-Ferchiou 1, 2, 11 , Marion Lambert 1, 2 , Stéphanie Dogniaux 3 , Frédéric Vély 4, 5 , Eric Vivier 4, 5 , Daniel Olive 6 , Stéphanie Dupuy 1 , Frank Levasseur 1 , David Zucman 7 , Céleste Lebbé 8 , Damien Sène 1, 2, 9 , Claire Hivroz 4 , Sophie Caillat-Zucman 1, 2, 10 1 Institut National de Recherche Médicale (INSERM) UMR1149, Centre de Recherche Sur l’Inflammation, Équipe Immunité Innée Chez l’enfant, Hôpital Robert Debré, Paris, France 2 Université Paris Diderot, Sorbonne Paris Cité, Paris, France 3 Institut Curie, Centre de Recherche, PSL Research University, INSERM U932 Immunité et Cancer, Paris, France 4 Centre d’Immunologie de Marseille-Luminy, Aix-Marseille Université UM2, INSERM U1104, CNRS UMR7280, Marseille, France 5 Immunologie, Hôpital de la Conception, Assistance Publique- Hôpitaux de Marseille, Marseille, France 6 Centre de Cancérologie de Marseille, INSERM U1068, Equipe Immunité et Cancer, Institut Paoli-Calmettes, Aix-Marseille Université, CNRS, UMR7258, Marseille, France 7 Hôpital Foch, Service de Médecine Interne, Suresnes, France 8 Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Département de Dermatologie, INSERM U976, Université Paris Diderot, Paris, France 9 Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Lariboisière, Département de Médecine Interne, Paris, France 10 Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Laboratoire d’Immunologie, Paris, France 11 Present address: Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor, Laboratoire d’Immunologie, Créteil, France Correspondence to: Sophie Caillat-Zucman, email: sophie.caillat@inserm.fr Keywords: NK cells, Kaposi sarcoma, PD-1, immune checkpoint, tumor escape Received: March 31, 2016 Accepted: September 13, 2016 Published: September 20, 2016 ABSTRACT Programmed Death-1 (PD-1), an inhibitory receptor expressed by activated lymphocytes, is involved in regulating T- and B-cell responses. PD-1 and its ligands are exploited by a variety of cancers to facilitate tumor escape through PD-1-mediated functional exhaustion of effector T cells. Here, we report that PD-1 is upregulated on Natural Killer (NK) cells from patients with Kaposi sarcoma (KS). PD-1 was expressed in a sub-population of activated, mature CD56 dim CD16 pos NK cells with otherwise normal expression of NK surface receptors. PD-1 pos NK cells from KS patients were hyporesponsive ex vivo following direct triggering of NKp30, NKp46 or CD16 activating receptors, or short stimulation with NK cell targets. PD-1 pos NK cells failed to degranulate and release IFNγ, but exogenous IL-2 or IL-15 restored this defect. That PD-1 contributed to NK cell functional impairment and was not simply a marker of dysfunctional NK cells was confirmed in PD-1-transduced NKL cells. In vitro , PD-1 was induced at the surface of healthy control NK cells upon prolonged contact with cells expressing activating ligands, i.e. a condition mimicking persistent stimulation by tumor cells. Thus, PD-1 appears to plays a critical role in mediating NK cell exhaustion. The existence of this negative checkpoint fine-tuning NK activation highlights the possibility that manipulation of the PD-1 pathway may be a strategy for circumventing tumor escape not only from the T cell-, but also the NK-cell mediated immune surveillance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“A link to persistent antigen exposure has been suggested [51].”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
Long, E. O., Sik Kim, H., Liu, D., Peterson, M. E., & Rajagopalan, S. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075005 · Cited by 1,217
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161
Modulation of natural killer cell activity by viruses
Lisnić, V. J., Krmpotić, A., & Jonjić, S. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.05.011 · Cited by 1,003
Targeting natural killer cells and natural killer T cells in cancer
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., & Brossay, L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3174 · Cited by 850
Self-citationOkazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 848
Lopez-Vergès, S., Milush, J. M., Schwartz, B. S., Pando, M. J., Jarjoura, J., York, V. A., Houchins, J. P., Miller, S., Kang, S.-M., Norris, P. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110900108 · Cited by 822
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
The PD-1–PD-L pathway in immunological tolerance
Okazaki, T., & Honjo, T. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.02.001 · Cited by 721
Brandt, C. S., Baratin, M., Yi, E. C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B., Ostrander, C. D., Kaifu, T., Chabannon, C., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090681 · Cited by 706
Self-citationSelf-tolerance of natural killer cells
Raulet, D. H., & Vance, R. E. (2006) · Nature Reviews Immunology · doi:10.1038/nri1863 · Cited by 608
Quigley, M., Pereyra, F., Nilsson, B., Porichis, F., Fonseca, C., Eichbaum, Q., Julg, B., Jesneck, J. L., Brosnahan, K., Imam, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2232 · Cited by 517
Said, E. A., Dupuy, F. P., Trautmann, L., Zhang, Y., Shi, Y., El-Far, M., Hill, B. J., Noto, A., Ancuta, P., Peretz, Y., et al. (2010) · Nature Medicine · doi:10.1038/nm.2106 · Cited by 481
Natural killer cells as an initial defense against pathogens
Lodoen, M. B., & Lanier, L. L. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.05.002 · Cited by 472
Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive, D., Moretta, L., Moretta, A., & Marcenaro, E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.025 · Cited by 465
Self-citationIshido, S., Wang, C., Lee, B.-S., Cohen, G. B., & Jung, J. U. (2000) · Journal of Virology · doi:10.1128/.74.11.5300-5309.2000 · Cited by 459
Functional Anatomy of T Cell Activation and Synapse Formation
Fooksman, D. R., Vardhana, S., Vasiliver-Shamis, G., Liese, J., Blair, D. A., Waite, J., Sacristán, C., Victora, G. D., Zanin-Zhorov, A., & Dustin, M. L. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101308 · Cited by 446
Evidence for discrete stages of human natural killer cell differentiation in vivo
Freud, A. G., Yokohama, A., Becknell, B., Lee, M. T., Mao, H. C., Ferketich, A. K., & Caligiuri, M. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052507 · Cited by 443
Natural Killer Cell Education and Tolerance
Orr, M. T., & Lanier, L. L. (2010) · Cell · doi:10.1016/j.cell.2010.08.031 · Cited by 441
IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0993 · Cited by 376
PD-1 is a novel regulator of human B-cell activation
Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2013) · International Immunology · doi:10.1093/intimm/dxs098 · Cited by 365
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Delahaye, N. F., Rusakiewicz, S., Martins, I., Ménard, C., Roux, S., Lyonnet, L., Paul, P., Sarabi, M., Chaput, N., Semeraro, M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2366 · Cited by 341
Self-citationNakamoto, N., Kaplan, D. E., Coleclough, J., Li, Y., Valiga, M. E., Kaminski, M., Shaked, A., Olthoff, K., Gostick, E., Price, D. A., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.033 · Cited by 299
NK cell education: not an on-off switch but a tunable rheostat
Brodin, P., Kärre, K., & Höglund, P. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.01.006 · Cited by 288
Bennett, F., Luxenberg, D., Ling, V., Wang, I.-M., Marquette, K., Lowe, D., Khan, N., Veldman, G., Jacobs, K. A., Valge-Archer, V. E., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.711 · Cited by 281
PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8 + T cells
Karwacz, K., Bricogne, C., MacDonald, D., Arce, F., Bennett, C. L., Collins, M., & Escors, D. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100165 · Cited by 265
A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation
Coscoy, L., & Ganem, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12432 · Cited by 250
How Do Natural Killer Cells Find Self to Achieve Tolerance?
Yokoyama, W. M., & Kim, S. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.006 · Cited by 206
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
Ardolino, M., Azimi, C. S., Iannello, A., Trevino, T. N., Horan, L., Zhang, L., Deng, W., Ring, A. M., Fischer, S., Garcia, K. C., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74337 · Cited by 191
Dittmer, D. P. (2003) · PubMed · Cited by 185
Gill, S., Vasey, A. E., De Souza, A., Baker, J., Smith, A. T., Kohrt, H. E., Florek, M., Gibbs, K. D., Tate, K., Ritchie, D. S., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415364 · Cited by 183
MacFarlane, A. W., Jillab, M., Plimack, E. R., Hudes, G. R., Uzzo, R. G., Litwin, S., Dulaimi, E., Al-Saleem, T., & Campbell, K. S. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0133 · Cited by 177
Robbins, S. H., Nguyen, K. B., Takahashi, N., Mikayama, T., Biron, C. A., & Brossay, L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.6.2585 · Cited by 159
Matta, J., Baratin, M., Chiche, L., Forel, J.-M., Cognet, C., Thomas, G., Farnarier, C., Pipéroglou, C., Papazian, L., Chaussabel, D., et al. (2013) · Blood · doi:10.1182/blood-2013-01-481705 · Cited by 159
Chang, W., Kim, J., Kim, Y., Kim, Y.-S., Lee, J.-M., Azuma, M., Yagita∥, H., & Kang, C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6707 · Cited by 154
Confinement of Activating Receptors at the Plasma Membrane Controls Natural Killer Cell Tolerance
Guia, S., Jaeger, B. N., Piatek, S., Mailfert, S., Trombik, T., Fenis, A., Chevrier, N., Walzer, T., Kerdiles, Y. M., Marguet, D., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001608 · Cited by 146
Joncker, N. T., & Raulet, D. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00658.x · Cited by 142
Alvarez, I. B., Pasquinelli, V., Jurado, J. O., Abbate, E. H., Musella, R. M., de la Barrera, S., & García, V. (2010) · The Journal of Infectious Diseases · doi:10.1086/654932 · Cited by 126
Wiesmayr, S., Webber, S. A., Macedo, C., Popescu, I., Smith, L., Luce, J., & Metes, D. (2011) · European Journal of Immunology · doi:10.1002/eji.201141832 · Cited by 118
Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Coudert, J. D., Desbois, M., Ghiringhelli, F., Viaud, S., Ryffel, B., Yagita∥, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3379 · Cited by 117
Golden‐Mason, L., Klarquist, J. S., Wahed, A. S., & Rosen, H. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.3637 · Cited by 112
Tuning the threshold of natural killer cell responses
Narni-Mancinelli, É., Ugolini, S., & Vivier, É. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.11.005 · Cited by 98
Early T Cell Signalling Is Reversibly Altered in PD-1+ T Lymphocytes Infiltrating Human Tumors
Renault, S., Fouquet, S., Chapon, M., Salmon, H., Régnier, F., Labroquère, K., Badoual, C., Damotte, D., Validire, P., Maubec, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017621 · Cited by 93
Wang, J. M., Cheng, Y., Shi, L., Ying, R. S., Wu, X. Y., Li, G. Y., Moorman, J. P., & Yao, Z. Q. (2013) · Journal of Virology · doi:10.1128/jvi.01515-13 · Cited by 76
Cheng, J., Ni, L., Zhang, Y., Zhang, C., Wu, X. Y., Atia, A. N., Thayer, P., Moorman, J. P., & Yao, Z. Q. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03382.x · Cited by 75
Dupuy, S., Lambert, M., Zucman, D., Choukem, S. P., Tognarelli, S., Pagès, C., Lebbé, C., & Caillat‐Zucman, S. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002486 · Cited by 67
Self-citationHüe, S., Monteiro, R. C., Berrih‐Aknin, S., & Caillat‐Zucman, S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.1909 · Cited by 54
Self-citationChen, Y., Wu, S., Guo, G., Fei, L., Guo, S. J., Yang, C., Fu, X., & Wu, Y. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001347 · Cited by 47
Rejuvenating exhausted T cells during chronic viral infection.
Okazaki, T., & Honjo, T. (2006) · Cell · doi:10.1016/j.cell.2006.01.022 · Cited by 40
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
Sivori, S., Vacca, P., Del Zotto, G., Munari, E., Mingari, M. C., & Moretta, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0206-4 · Cited by 555
Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 494
Metadata
- Authors
- Beldi-Ferchiou, A., Lambert, M., Dogniaux, S., Vély, F., Vivier, E., Olive, D., Dupuy, S., Levasseur, F., Zucman, D., Lebbé, C., Sène, D., Hivroz, C., & Caillat-Zucman, S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-09-20
- Volume
- 7
- Issue
- 45
- Pages
- 72961-72977
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2462014591
- Cited by
- 312
- References
- 69
- FWCI
- 15.98
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.